CLCN1 and myotonic dystrophy type 1: The drug appeared to modify the alternative splicing of a subset of genes associated with DM1 in these cell models, as it partially rescued the aberrant splicing of INSR E11, CLCN1 E7a, TNNT2 E5, ATP2A1 E22, and DMD E78.